Cellular senescence throws new insights into patient classification and pharmacological interventions for clinical management of hepatocellular carcinoma

Figure 8 Assessment of the cellular senescence-relevant gene signature in predicting efficacy of pharmacological interventions in TCGA-LIHC dataset. A–D: IC₅₀ value of cisplatin, doxorubicin, gemcitabine, and sorafenib in low- and high-RiskScore hepatocellular carcinomas (HCCs); E: Abundance of the tumor microenvironment components inferred by multiple algorithms; F–K: Comparison of carcinoma-associated fibroblast (CAF), myeloid-derived suppressor cell (MDSC), interferon gamma (IFNG), dysfunction score, exclusion score and Tumor Immune Dysfunction and Exclusion levels in low- and high-RiskScore HCCs. ^cP < 0.001. ns: No significant difference.